Incyte Corp. About
Incyte Corp. Incyte has active internal drug discovery programs
focused on the identification of novel small molecule drugs for inflammation,
cancer and diabetes
and they recently entered into a collaborative license agreement for Reverset™,
a novel nucleoside analog reverse transcriptase inhibitor, which is in Phase II
development to treat human immunodeficiency
virus (HIV) infections.
Reverset -- HIV CCR2
Antagonists -- Rheumatoid
Arthritis, MS,
Neuropathic Pain, Atherosclerosis Sheddase
Inhibitors -- Cancer More
on Incyte Key
Statistics for Incyte
Basic
Chart for Incyte